



ENDRA Life Sciences Inc.

Reports Q4. FDA timeline delayed likely to 2025. We believe FDA approval and EU/US product launch over the next year to drive stock. Lowering P/T to \$10.

Q4 about inline: ENDRA recently (on March 28) reported its Q4 2023 (ending December) results. Net loss was \$1.5 million or EPS of \$(0.17) compared with our estimates of \$(0.36). There was no Q4 guidance or consensus estimates. ENDRA is a late stage medical device development/early stage commercialization company so it generates no revenues.

Operating expense: Operating expenses were \$1.5 million, vs \$3.1 million in Q3 on lower R&D costs.

No 2024 guidance: Management did not provide 2024 financial guidance.

Adjusting 2024 estimates: We are adjusting our 2024 estimates for revenues to \$0.2 from \$1.0 million, and for EPS to \$(1.06) from \$(1.41).

Focused on TAEUS development: ENDRA has one main medical device candidate, the Thermo Acoustic Enhanced UltraSound (TAEUS) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT and MRI, but at a fraction of the cost and at the point-of-care.

FDA submission done: On August 14, 2023, ENDRA filed its De Novo application with the FDA. After extensive dialogue with the FDA, ENDRA is (as of February 2022) pursuing the De Novo pathway for its TAEUS System (and withdrawing its 510(k) application), which is intended to characterize fatty liver tissue as a non-invasive means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD).

FDA decision delayed likely to 2025: The FDA's target approval date is 150 days (~5 months or about January 15, 2024). However, the FDA has requested for more information and ENDRA will meet with the FDA soon to discuss any new requirements or timeline to get approval. This may include additional data and a new submission for approval in 1H 2025. We note that key commercialization activities have already started, including a major distribution deal in Vietnam.

EU launched: In March 2020, ENDRA received CE Mark approval, and is now starting initial commercialization activity in Europe.

Over 200 scans done: ENDRA has 4 U.S. reference evaluation sites, 5 in the EU, and a site in China used to build clinical evidence and establish the clinical utility of the TAEUS device for assessing NAFLD-NASH. ENDRA has over 200 total patients scanned to date.

Large market opportunity: The company is launching its first TAEUS application to measure fat in the liver, which is used for early detection and monitoring of Steatotic Liver Disease (SLD) (aka Non-Alcoholic Fatty Liver Disease (NAFLD)). In 2011, over 1.4 billion people were affected by SLD/NAFLD/NASH around the world. Despite the increased incidence of SLD/NAFLD, there are no low-cost, accurate, and safe methods for measuring fat in the liver. TAEUS technology should enable to diagnose SLD earlier and monitor patients with related liver diseases more accurately and cost-effectively than is possible with existing technology.

Balance sheet: In Q4, ENDRA has \$3 million in cash and no debt. We believe it needs to raise cash currently.

Current valuation attractive: Maintaining our BUY rating, but lowering our 12-month price target to \$10 from \$11. This is based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Ann Arbor, MI, ENDRA Life Sciences is a medical device company developing enhanced ultrasound technologies (TAEUS) for medical imaging.

United States
Healthcare

April 30, 2024

Edward Woo, CFA
(561) 327-9435
ewoo@ascendant.com

COMPANY UPDATE

Rating: **BUY**

Ticker: NDRA

Price: \$0.29
(intraday)

Target: \$10
(from \$11)

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$0.22 – 2.79
Shares Outstanding (million):	11
Market cap (\$million):	\$3
EV (\$million):	\$0
Debt (\$million):	\$0
Cash (\$million):	\$3
Avg. Daily Trading Vol. (\$million):	\$0.2
Float (million shares):	11
Short Interest (million shares):	0.1
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2024E</u> <u>(Cur.)</u>	<u>2024E</u> <u>(Old)</u>	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>
Q1 Mar	0.0E	0.1E	0.1E	
Q2 Jun	0.0E	0.1E	0.1E	
Q3 Sep	0.1E	0.3E	0.3E	
Q4 Dec	<u>0.1E</u>	<u>0.5E</u>	<u>0.5E</u>	
Total	0.2E	1.0E	1.0E	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	<u>2024E</u> <u>(Cur.)</u>	<u>2024E</u> <u>(Old)</u>	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>
Q1 Mar	(0.27)E	(0.37)E	(0.27)E	
Q2 Jun	(0.27)E	(0.36)E	(0.26)E	
Q3 Sep	(0.26)E	(0.35)E	(0.25)E	
Q4 Dec	<u>(0.26)E</u>	<u>(0.33)E</u>	<u>(0.25)E</u>	
Total	(1.06)E	(1.41)E	(1.04)E	
P/E	N/A		N/A	

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 12.

Exhibit 1: Q4 2023 and Recent Highlights (as of March 28, 2024)

Highlights from the fourth quarter of 2023 and recent weeks include:

- **Installed first TAEUS system in the UK at King's College Hospital for clinical evaluation.** King's College Hospital NHS Foundation Trust (KCH) in London is one of the leading centers of excellence in the United Kingdom's National Health Service (NHS). KCH will use ENDRA's TAEUS liver system in a clinical study to compare its liver fat assessment accuracy with MRI, the acknowledged research standard. This study is expected to include approximately 75 subjects and is intended to provide essential data to evaluate the TAEUS technology's performance.
- **FDA's review of ENDRA's De Novo request is ongoing.** In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA. In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA. As a result, ENDRA has had several interactions with and provided additional details to the FDA. These efforts have fostered a better understanding of the FDA's expectations, which ENDRA is working to achieve. ENDRA has confirmed an in-person FDA meeting in the second quarter of 2024.
- **Showcased the TAEUS system at key hepatology, endocrinology and radiology medical conferences in the U.S. and Europe.** During the fourth quarter and recent weeks, the ENDRA team met with prospective customers, industry leaders and key partners at four major clinical conferences, including The Liver Meeting by the American Association for the Study of Liver Diseases. During The Liver Meeting, ENDRA also hosted an offsite panel discussion with multidisciplinary key opinion leaders in the fields of hepatology, endocrinology and radiology to share their unique perspectives on managing Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- **Expanded intellectual property portfolio to 75 issued patents globally.** During the fourth quarter of 2023 and recent weeks, ENDRA was issued seven additional patents, including three in the U.S., one in Europe and three in China. The company is actively exploring licensing opportunities in non-core indications to augment the value of its growing intellectual property portfolio.
- **New ICD-10-CM code issued, which paves the way for improved NAFLD diagnostics.** The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), a global coding system used to indicate a diagnosis for reimbursement purposes and issued by the World Health Organization, included NAFLD under the ICD-10 K76.0 code. This facilitates standardized billing for the diagnosis of NAFLD, is applicable across the U.S., Europe and other regions, and promotes consistency in medical documentation and insurance processes. ENDRA believes the issuance of the ICD-10 K76.0 code specifically for NAFLD measurement represents a significant opportunity for innovation in liver health diagnostics as healthcare providers now have a clearer pathway to integrate advanced diagnostic technologies, including the TAEUS system.

Source: Company reports.

Exhibit 2: ENDRA Investment Highlights

ENDRA Life Sciences

ENHANCE ULTRASOUND TO SEE HUMAN TISSUE IN WAYS SIMILAR TO CT-MRI... BUT AT 50X LOWER COST²

ENDRA Life Sciences: Business Highlights



PROPRIETARY PLATFORM

- Thermo Acoustic Enhanced Ultrasound (TAEUS[®]): RF pulses → sonic waves
- Similar to MRI but 1/50th the cost³ and at point of patient care
- Multiple potential clinical applications & revenue streams
- CE mark received in Europe
- FDA De Novo request filed in U.S.
- 67 patents issued, all by ENDRA



MULTIBILLION \$ MARKET

- 1st TAEUS application: Measure liver fat for assessment of Steatotic Liver Disease (SLD)
- Affects over 2 billion people¹ globally
- Diagnostic gap: No safe, easy-to-use, cost-effective tools
- \$12.5 billion diagnostic market opportunity²



CAPITAL-EFFICIENT MODEL

- Lean and deeply experienced ENDRA team
- World-class technical, clinical & commercial partners

Source: Company reports.

Exhibit 3: TAEUS 2023 Milestones

Anticipated Milestones

2023

- ✓ Collect 200+ TAEUS subject scans to support development, regulatory & commercial needs
- ✓ Publish first independent TAEUS clinical abstract: EASL¹ Annual Meeting, June 2023
- ✓ File U.S. FDA De Novo request for TAEUS Fatty Liver application, August 2023
- ✓ Publish second independent TAEUS clinical abstract: EASL-SLD¹ Summit, September 2023
- ✓ Expand intellectual property portfolio
- Continue to bolster clinical data of TAEUS system with additional scans, activation of new clinical partner sites, and peer-reviewed abstracts/publications
- Achieve sales in Europe
- Forge alliances with med-techs for TAEUS application development and licensing

Source: Company reports.

Exhibit 4: ENDRA Partners

ENDRA Value-Added Partner Ecosystem

LEVERAGE PARTNERSHIPS TO AMPLIFY ENDRA'S TECHNICAL, CLINICAL & COMMERCIAL ACTIVITIES

TECHNOLOGY LEADERSHIP

- Enhance peer-leading IP portfolio
- Real-time guidance tools
- Novel cloud-based data mgt.
- Artificial Intelligence tools
- Collaborations to co-develop & integrate TAEUS applications



ROBUST CLINICAL EVIDENCE

- Clinical data supporting regulatory submissions & commercialization
- Studies comparing TAEUS to MRI-PDFF in target markets: U.S., EU, Asia
- Pharma pilots of TAEUS for drug trial recruitment efficiencies



COMMERCIAL ADOPTION

- Target clinicians at local level in key markets w/ENDRA team & partners
- Demonstrate TAEUS at key global clinical conferences
- Online education & marketing
- CRM w/5000 clinicians
- Leverage clinical publications & reference sites




Source: Company reports.

Exhibit 5: ENDRA's TAEUS Liver Fat Opportunity (Steatotic Liver Disease (SLD) aka NASH - NAFLD)


The Problem: Steatotic Liver Disease (SLD)

CONVERGENCE OF PIVOTAL FACTORS CREATE OPPORTUNITY FOR ENDRA TO ADDRESS LARGE UNMET DIAGNOSTIC NEED




The Opportunity: Improved Diagnostics To Drive Adoption of New Treatments

FIRST APPROVED STEATOTIC LIVER DISEASE (SLD) THERAPIES EXPECTED IN 2023^{1,2} INTENSIFYING NEED TO IDENTIFY & MONITOR PATIENTS



The Opportunity: Assess Liver Fat of 2+ Billion SLD Patients

INTRODUCE A TOOL THAT BALANCES DIAGNOSTIC VALUE + ACCESSIBILITY



Source: Company reports.

Exhibit 6: TAEUS

Thermo Acoustic Enhanced Ultrasound: TAEUS®


FIRST APPLICATION: NON-INVASIVE LIVER FAT ASSESSMENT TOOL

TAEUS SYSTEM


- System consists of a console, probe and display
- Analyzes tissue chemistry, like MRI, rather than structural properties of tissue like traditional ultrasound
- Self-calibrating, for uniform measures across individuals & devices
- Low sensitivity to fibrosis,¹ a confounding factor in MASLD
- Total procedure ~10 minutes

CLINICAL VALIDATION & REGULATORY STATUS

- Over 200 TAEUS subject scans performed
- CE Mark received in Europe
- Peer-reviewed clinical abstract published @ 2023 EASL²
- FDA De Novo request submitted
 - Sensitivity of 90% at 6% liver fat threshold
 - TAEUS correlation to MRI-PDFF: r=0.78




Commercializing TAEUS Liver: 3 Core Elements



Source: Company reports.


Exhibit 7: TAEUS Potential Market Opportunities

Total Addressable Markets for TAEUS®: Liver & Other Applications




ENDRA's TAEUS® Platform & Business Model

FIRST TAEUS APPLICATION ASSESSES LIVER FAT, WITH LICENSING OPPORTUNITIES IN OTHER INDICATIONS



Source: Company reports.

Exhibit 8: ENDRA Life Sciences Stock Price (5-years)



Source: <https://bigcharts.marketwatch.com/>

FINANCIAL MODEL

ENDRA Life Sciences Inc.

Income Statement (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.3	0.5	1.0
<u>Cost of Revenues</u>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.5
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.5
Research and development	1.2	1.8	1.8	1.7	6.6	1.4	1.4	1.6	0.6	5.0	1.1	1.1	1.1	1.1	4.4	1.2	1.2	1.2	1.3	4.9
Sales and marketing	0.3	0.3	0.4	0.3	1.4	0.2	0.2	0.2	0.1	0.8	0.5	0.5	0.5	0.5	2.0	0.5	0.5	0.5	0.5	2.0
General and administrative	1.3	1.4	1.2	1.3	5.2	1.4	1.3	1.3	0.7	4.7	1.4	1.4	1.4	1.4	5.6	1.4	1.4	1.4	1.4	5.6
<u>Restructuring and other</u>					0.0					0.0					0.0					0.0
Total operating expenses	2.9	3.6	3.4	3.3	13.2	2.9	3.0	3.1	1.5	10.5	3.0	3.0	3.0	3.0	12.0	3.1	3.1	3.1	3.2	12.5
Operating income (loss)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(3.0)	(3.1)	(1.5)	(10.5)	(3.0)	(3.0)	(3.0)	(3.0)	(11.9)	(3.1)	(3.1)	(3.0)	(3.0)	(12.0)
Interest income (expense)					0.0	(0.0)			0.0	0.0	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
<u>Other income (expense)</u>	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.4	0.0	(0.0)		0.5					0.0					0.0
Income before income taxes	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(3.0)	(3.0)	(3.0)	(3.0)	(11.9)	(3.1)	(3.1)	(3.0)	(3.0)	(12.0)
<u>Income taxes</u>					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(3.0)	(3.0)	(3.0)	(3.0)	(11.9)	(3.1)	(3.1)	(3.0)	(3.0)	(12.0)
<u>Nonrecurring/noncash adjustments</u>					0.0					0.0					0.0					0.0
Net income (pro forma)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(3.0)	(3.0)	(3.0)	(3.0)	(11.9)	(3.1)	(3.1)	(3.0)	(3.0)	(12.0)
EBITDA																				
Shares, Basic	2.2	3.1	3.2	3.2	2.9	3.2	6.0	7.7	8.6	6.4	11.0	11.1	11.2	11.3	11.2	11.4	11.5	11.6	11.7	11.6
Shares, Diluted	2.2	3.1	3.2	3.2	2.9	3.2	6.0	7.7	8.6	6.4	11.0	11.1	11.2	11.3	11.2	11.4	11.5	11.6	11.7	11.6
EPS Basic (Pro forma)	(\$1.33)	(\$1.17)	(\$1.09)	(\$1.04)	(\$4.56)	(\$0.93)	(\$0.43)	(\$0.40)	(\$0.17)	(\$1.58)	(\$0.27)	(\$0.27)	(\$0.26)	(\$0.26)	(\$1.06)	(\$0.27)	(\$0.26)	(\$0.25)	(\$0.25)	(\$1.04)
EPS Diluted (Pro forma)	(\$1.33)	(\$1.17)	(\$1.09)	(\$1.04)	(\$4.56)	(\$0.93)	(\$0.43)	(\$0.40)	(\$0.17)	(\$1.58)	(\$0.27)	(\$0.27)	(\$0.26)	(\$0.26)	(\$1.06)	(\$0.27)	(\$0.26)	(\$0.25)	(\$0.25)	(\$1.04)
Margins																				
Gross margin											50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Research and development											#DIV/0!	#DIV/0!	1100%	1100%	2200%	1200%	1200%	400%	260%	490%
Sales and marketing											#DIV/0!	#DIV/0!	500%	500%	1000%	500%	500%	167%	100%	200%
General and administrative											#DIV/0!	#DIV/0!	1400%	1400%	2800%	1400%	1400%	467%	280%	560%
Operating margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	#####	#####	#####	-3050%	-3050%	-983%	-590%	#####
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	#####	#####	#####	-3051%	-3051%	-984%	-590%	#####
YY % change																				
Total Revenue											#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#####	#DIV/0!	#DIV/0!	200%	400%	400%
Gross margin											#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#####	#DIV/0!	#DIV/0!	200%	400%	400%
Research and development	6%	6%	56%	17%	20%	15%	-24%	-11%	-65%	-24%	-21%	-21%	-33%	90%	-12%	9%	9%	9%	18%	11%
Sales and marketing	111%	33%	53%	-14%	33%	-47%	-28%	-42%	-55%	-43%	175%	102%	105%	238%	144%	0%	0%	0%	0%	0%
General and administrative	2%	15%	-3%	4%	5%	5%	-3%	7%	-45%	-9%	2%	4%	12%	92%	19%	0%	0%	0%	0%	0%
Operating income (loss)	11%	12%	29%	8%	14%	3%	-16%	-8%	-56%	-20%	2%	0%	-6%	102%	13%	2%	2%	0%	0%	1%
Net income (loss)	20%	12%	29%	6%	16%	3%	-29%	-10%	-56%	-24%	2%	17%	-5%	102%	18%	2%	2%	0%	0%	1%
EPS Diluted (Pro forma)	5%	-24%	-14%	-29%	-18%	-30%	-63%	-63%	-84%	-65%	-71%	-37%	-35%	53%	-33%	-2%	-2%	-3%	-3%	-3%

Source: Company reports and Ascendant Capital Markets estimates.

ENDRA Life Sciences Inc.

Balance Sheet (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	7.1	11.3	8.0	4.9	2.4	4.8	3.3	2.8	0.6	(2.1)	(4.7)	(7.3)	(10.1)	(12.9)	(15.3)	(17.6)
Short term investments									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable, net									0.0	0.0	0.1	0.1	0.1	0.1	0.3	0.6
Inventory	1.9	2.4	2.6	2.6	2.7	2.8	2.8		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	1.1	0.8	0.9	1.0	0.4	0.5	0.3	0.2	0.0	0.0	0.1	0.1	0.1	0.1	0.2	0.3
Total current assets	10.1	14.5	11.6	8.5	5.5	8.1	6.4	3.0	0.6	(2.1)	(4.5)	(7.2)	(10.0)	(12.7)	(14.7)	(16.8)
Property and equipment, net	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Intangibles, net									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory								2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.6	0.6	0.5	0.5	0.9	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total assets	10.9	15.3	12.3	9.3	6.7	9.2	7.6	6.8	3.3	0.6	(1.8)	(4.5)	(7.3)	(10.1)	(12.1)	(14.1)
Liabilities and stockholders' equity																
Accounts payable	1.2	1.4	1.6	1.5	1.6	1.8	2.0	0.7	0.0	0.0	0.3	0.3	0.3	0.3	0.9	1.5
Accrued expenses									0.0	0.0	0.1	0.1	0.1	0.1	0.2	0.3
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Short term debt				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total current liabilities	1.4	1.5	1.7	1.7	1.8	2.0	2.2	0.9	0.2	0.2	0.6	0.6	0.6	0.6	1.3	2.0
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.5	0.4	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Long term debt	0.0	0.0	0.0						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Preferred stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.8	1.0	1.3	1.5	1.8	2.0
Additional paid-in capital	80.6	88.5	88.8	89.1	89.3	94.3	95.7	97.6	97.6	97.6	97.6	97.6	97.6	97.6	97.6	97.6
Retained earnings	(71.5)	(75.1)	(78.6)	(81.9)	(84.8)	(87.4)	(90.5)	(91.9)	(94.9)	(97.9)	(100.9)	(103.8)	(106.9)	(109.9)	(112.9)	(115.8)
Accumulated other comprehensive income									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	9.1	13.3	10.2	7.2	4.5	6.9	5.2	5.7	2.9	0.2	(2.5)	(5.2)	(8.0)	(10.8)	(13.5)	(16.2)
Total stockholders' equity and liabil	10.9	15.3	12.3	9.3	6.7	9.2	7.6	6.8	3.3	0.6	(1.8)	(4.5)	(7.3)	(10.1)	(12.1)	(14.1)

Balance Sheet Drivers

	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev									50%	50%	50%	50%	50%	50%	50%	50%
Accounts payable as % of total rev									300%	300%	300%	300%	300%	300%	300%	300%
Inventories as % of cost of rev									20%	20%	20%	20%	20%	20%	20%	20%
Accrued expenses as % of total rev									50%	50%	50%	50%	50%	50%	50%	50%
Activity Ratios																
A/R Days Sales Outstanding									100	100	100	100	100	100	100	100
Inventory Turnover									#DIV/0!	#DIV/0!	20.0x	20.0x	20.0x	20.0x	20.0x	20.0x
A/P Days Payable									#DIV/0!	#DIV/0!	540	540	540	540	540	540
Book & Cash Value (per share)																
Book Value per Share (diluted)	\$4.21	\$4.33	\$3.23	\$2.27	\$1.42	\$1.16	\$0.68	\$0.66	\$0.26	\$0.01	-\$0.23	-\$0.46	-\$0.70	-\$0.94	-\$1.16	-\$1.38
Cash per Share (diluted)	\$3.31	\$3.66	\$2.54	\$1.54	\$0.74	\$0.80	\$0.43	\$0.33	\$0.05	-\$0.19	-\$0.41	-\$0.65	-\$0.89	-\$1.12	-\$1.31	-\$1.50
Net cash per Share (diluted)	\$3.30	\$3.65	\$2.53	\$1.53	\$0.73	\$0.80	\$0.43	\$0.33	\$0.05	-\$0.19	-\$0.42	-\$0.65	-\$0.89	-\$1.12	-\$1.31	-\$1.50

Source: Company reports and Ascendant Capital Markets estimates

ENDRA Life Sciences Inc.


Cash Flow Statement (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025	
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E	
Cash flow from operating activities																					
Net income	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(3.0)	(3.0)	(3.0)	(3.0)	(11.9)	(3.1)	(3.1)	(3.0)	(3.0)	(12.0)	
Depreciation	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	
Amortization	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Debt related amortization expense					0.0					0.0					0.0					0.0	
Stock comp	0.3	0.3	0.3	0.3	1.2	0.2	0.3	0.3	0.3	1.0	0.3	0.3	0.3	0.3	1.0	0.3	0.3	0.3	0.3	1.0	
Deferred income taxes					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in fair value of warrant liability					0.0					0.0					0.0					0.0	
Writedowns and impairments				0.0	0.0				0.2	0.2					0.0					0.0	
Other gains/losses					0.0					0.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Changes in operating assets and liabilities:																					
Accounts receivable					0.0					0.0	0.0	0.0	(0.1)	0.0	(0.1)	0.0	0.0	(0.2)	(0.2)	(0.4)	
Inventory	(0.6)	(0.4)	(0.3)	(0.0)	(1.4)	(0.1)	(0.0)	0.0	(0.0)	(0.1)	0.0	0.0	(0.0)	0.0	(0.0)	0.0	0.0	(0.0)	(0.0)	(0.0)	
Prepaid expenses & other curre	0.3	0.2	(0.1)	(0.1)	0.4	0.1	(0.2)	0.1	0.1	0.2	0.2	0.0	(0.1)	0.0	0.1	0.0	0.0	(0.1)	(0.1)	(0.2)	
Income tax					0.0					0.0					0.0					0.0	
Other assets					0.0					0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	
Accounts payable	(0.2)	0.1	0.2	(0.0)	0.1	0.1	0.2	0.1	(1.3)	(0.8)	(0.7)	0.0	0.3	0.0	(0.4)	0.0	0.0	0.6	0.6	1.2	
Accrued expenses					0.0					0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.2	
Other liabilities	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Net cash (used in) provided by	(3.1)	(3.3)	(3.2)	(3.1)	(12.769)	(2.5)	(2.3)	(2.6)	(2.2)	(9.5)	(2.2)	(2.7)	(2.5)	(2.7)	(10.1)	(2.8)	(2.8)	(2.3)	(2.3)	(10.2)	
Cash flow from investing activities																					
Purchases of property and equi	(0.1)	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)			0.0	(0.0)	0.0	0.0	(0.0)	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.1)	
Purchases of short-term investments					0.0					0.0					0.0					0.0	
Acquisitions					0.0					0.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Net cash used in investing activ	(0.1)	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)	0.0	0.0	0.0	(0.0)	0.0	0.0	(0.0)	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.1)	
Cash flow from financing activities																					
Issuance of debt					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Repayment of debt					0.0					0.0					0.0					0.0	
Issuance of stock	0.9	7.5			8.4		4.7	1.1	0.7	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Proceeds from stock option exercises					0.0		0.0		1.0	1.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Dividends and distributions					0.0					0.0					0.0					0.0	
Cash provided by (used in) fina	0.9	7.5	0.0	0.0	8.4	0.0	4.7	1.1	1.7	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Effect of exchange rate on cash					0.0					0.0					0.0					0.0	
Net increase (decrease) in cash	(2.3)	4.2	(3.3)	(3.1)	(4.6)	(2.5)	2.5	(1.5)	(0.5)	(2.1)	(2.2)	(2.7)	(2.5)	(2.7)	(10.2)	(2.8)	(2.8)	(2.3)	(2.3)	(10.3)	
Beginning cash and equivalents	9.5	7.1	11.3	8.0	9.5	4.9	2.4	4.8	3.3	4.9	2.8	0.6	(2.1)	(4.7)	2.8	(7.3)	(10.1)	(12.9)	(15.3)	(7.3)	
Ending cash and equivalents	7.1	11.3	8.0	4.9	4.9	2.4	4.8	3.3	2.8	2.8	0.6	(2.1)	(4.7)	(7.3)	(7.3)	(10.1)	(12.9)	(15.3)	(17.6)	(17.6)	

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

ENDRA Life Sciences Inc.



Source: <https://bigcharts.marketwatch.com/>

Report	Report Date	Rating	Price Target
1	4/10/2019	Buy	90.00
2	5/15/2019	Buy	85.00
3	8/12/2019	Buy	65.00
4	11/18/2019	Buy	55.00
5	1/28/2020	Buy	60.00
6	3/29/2020	Buy	50.00
7	5/19/2020	Buy	55.00
8	8/18/2020	Buy	65.00
9	11/21/2020	Buy	70.00
10	4/4/2021	Buy	110.00
11	5/31/2021	Buy	120.00
12	8/23/2021	Buy	130.00
13	11/17/2021	Buy	125.00
14	4/12/2022	Buy	110.00
15	6/5/2022	Buy	100.00
16	9/7/2022	Buy	90.00
17	11/21/2022	Buy	85.00
18	3/28/2023	Buy	30.00
19	5/30/2023	Buy	20.00
20	8/25/2023	Buy	17.00
21	11/20/2023	Buy	11.00

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street

Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product/device candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech/medtech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of April 15, 2024)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	55	98%	18	33%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	56	100%	18	32%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.